It Can Move Now. It Still Has to Listen First.

The pilot that lets AI reach patients early#

Four generative AI medical devices, including two named as Cadence and Limbic, were recently accepted into a Food and Drug Administration pilot called TEMPO, which lets a generative AI device reach patients before it completes full marketing authorisation. STAT News broke the story on 3 September 2026. The FDA's own TEMPO for Digital Health Devices page confirms the mechanism: it ties into CMS's ten-year ACCESS model, which began on 5 July 2026 and covers four chronic-condition tracks, early cardio-kidney-metabolic disease, cardio-kidney-metabolic disease, musculoskeletal pain and behavioural health.

The point of TEMPO is not to skip authorisation. It is to let the FDA and a device maker gain real-world, hands-on experience with a generative AI product inside an active care setting, before the formal review concludes. That distinction, provisional access rather than approval, is the whole story for anyone doing ai in healthcare marketing for a device in this pilot, and it is exactly the distinction most marketing copy is built to blur.

Why AI in healthcare marketing gets harder, not easier#

Every FDA-adjacent marketing brief already has to answer one question honestly: what does this product's actual authorisation status let you say. AI in healthcare marketing has a second, newer version of that question, because a generative AI device's behaviour can genuinely change between the pilot and the final cleared version, in a way a fixed diagnostic imaging algorithm's does not. Marketing copy written for the pilot version may need to be rewritten for the cleared one, not because the law changed, but because the product did.

The FDA has been building towards this for years. Its Artificial Intelligence and Software as a Medical Device programme published its first AI/ML Action Plan in January 2021, finalised its Predetermined Change Control Plan guidance in December 2024, and issued draft lifecycle-management guidance in January 2025. TEMPO, launching its first cohort in July 2026, is the newest branch of that same tree: a regulator trying to build a framework for a category of device that keeps learning after it ships.

Where the claims line actually sits#

The Federal Trade Commission, not just the FDA, has authority here, and its Health Products Compliance Guidance sets a demanding bar: a health claim needs competent and reliable scientific evidence behind it, and the FTC judges an advertisement by its net impression, meaning the overall message a reasonable consumer takes away, not just the literal words used. A device page that says available now without stating its TEMPO status creates exactly the impression the FTC's guidance warns against: that the product has cleared a bar it has not yet cleared.

The FDA also keeps a public, running list of AI-enabled medical devices it has authorised, a resource any medical device marketing agency should treat as a first stop before writing a comparative claim. Naming a device as one of the first, or the only, AI product of its kind is a factual claim, and the FDA's own list is the fastest way to check whether it is actually true.

Ai medical device regulation is not one rulebook, it is three#

A marketing team working across the United States and Europe is not managing one set of rules. The FDA's TEMPO pathway, the FTC's advertising-claims standard, and the European Union's Medical Device Regulation all apply different tests to what a device may say about itself, and a device accepted into a US pilot programme has no equivalent status in the EU at all. Ai medical device regulation is, in practice, three overlapping compliance conversations happening at once, and a marketing claim cleared for one jurisdiction can still be a liability in another.

The fda pilot pathway itself is narrow by design. Four devices accepted so far is not an open door; it is a controlled test the FDA can close, adjust, or widen depending on what the first cohort's real-world results show. Any marketing plan built on the assumption that TEMPO access will simply continue is planning on a policy choice, not a settled fact.

This is precisely where a medical device marketing agency earns its fee. Getting the headline right is easy. Getting the fine print, the disclosure line, the FAQ answer and the sales deck footer all consistently right, across every asset a device touches, is the actual job, and it is a job that changes the moment a device graduates from pilot to full authorisation.

Patient data adds a fourth layer most launch teams forget until it is too late. Any generative AI device gathering clinical data from a live patient population sits inside the HHS HIPAA framework as well, and a marketing claim describing how a device learns from real-world use needs to be checked against what the device is actually permitted to collect and disclose, not just what the FDA has cleared it to do clinically.

How to market a pilot device without overreaching#

A fox does not announce a kill before it has closed its jaws. Picking up a scent along the trail is not the same as reaching the den with something to show for it, and a pilot pathway is not a clearance letter. The discipline required here is the same one that keeps a hunt honest: say only what has actually happened, not what is expected to happen next. A quarry only half-caught, dressed up as a finished hunt, fools nobody for long, least of all a regulator who reads the fine print for a living.

Name the pathway, do not hide it#

State plainly that a device is participating in FDA's TEMPO pilot, tied to the CMS ACCESS model. Patients, clinicians and payers researching the device deserve to know its actual regulatory status, and burying it erodes exactly the trust a new AI product needs most. This is the single most consistent lesson from every credible practitioner writing about ai in healthcare marketing this year: the audience forgives a limitation stated plainly far more readily than one it discovers on its own.

Separate marketing copy from clinical claims#

A line explaining how the device works, in plain language, is marketing. A line asserting an outcome, an accuracy rate, or a comparison to a clinician's judgement is a clinical claim, and it needs the evidence to match. Keep the two visibly, structurally separate in every asset.

Where a claim cannot be written to satisfy both the FDA's pilot status and the FTC's evidence standard at once, it is the wrong claim, not an inconvenient rule. The same logic applies to a company that wants to market a medical device without FDA approval outright, before any pilot or clearance exists: the honest version of that story is always the story about the process, the trial data, the roadmap, never a claim about outcomes the device has not yet demonstrated under any regulator's review. The ACCESS model's own request for applications is a useful model for that kind of honesty: it describes outcomes it expects to measure, not outcomes it has already achieved.

The commercial argument for getting this right#

A device maker that markets its TEMPO status honestly gets something a hedged, vague launch cannot: a genuinely differentiated story. Being the first generative AI device patients can actually access under a named FDA pathway is newsworthy, fundable and clinically interesting on its own terms, without needing to borrow the authority of a full clearance it has not earned yet. This is what good ai in healthcare marketing looks like when the product itself is still moving.

For any ai in healthcare marketing team advising one of the four devices now inside TEMPO, or the next cohort likely to follow it, the brief writes itself once the claims line is respected: explain the pathway, name the oversight, show the real-world evidence as it accumulates, and let the device earn its full authorisation in public rather than pretending it has already arrived. A hedged claim ages badly. An honest one gets sharper every month the pilot runs, and that is the version of ai in healthcare marketing worth building a whole launch around.

Frequently asked questions#